CA3177169A1 - Anticorps contre sars-cov-2 - Google Patents

Anticorps contre sars-cov-2 Download PDF

Info

Publication number
CA3177169A1
CA3177169A1 CA3177169A CA3177169A CA3177169A1 CA 3177169 A1 CA3177169 A1 CA 3177169A1 CA 3177169 A CA3177169 A CA 3177169A CA 3177169 A CA3177169 A CA 3177169A CA 3177169 A1 CA3177169 A1 CA 3177169A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
antibody
antigen
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3177169A
Other languages
English (en)
Inventor
Davide Corti
Matteo Samuele PIZZUTO
Dora PINTO
Martina BELTRAMELLO
Anna De Marco
Elisabetta CAMERONI
Gyorgy Snell
Nadine CZUDNOCHOWSKI
Colin HAVENAR-DAUGHTON
Florian A. Lempp
Amalio Telenti
Fabrizia ZATTA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vir Biotechnology Inc
Original Assignee
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc filed Critical Vir Biotechnology Inc
Publication of CA3177169A1 publication Critical patent/CA3177169A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente divulgation concerne des anticorps et des fragments de liaison à l'antigène de ceux-ci qui peuvent se lier à un antigène du SARS-CoV-2 et, dans certains modes de réalisation, peuvent neutraliser puissamment une infection par SARS-CoV-2. La divulgation concerne également des polynucléotides qui codent pour des anticorps et des fragments de liaison à l'antigène, des vecteurs, des cellules hôtes, et des compositions et des utilisations associées, notamment pour la prévention, le traitement et le diagnostic d'une infection par SARS-CoV-2 ou un autre coronavirus.
CA3177169A 2020-05-08 2021-05-07 Anticorps contre sars-cov-2 Pending CA3177169A1 (fr)

Applications Claiming Priority (29)

Application Number Priority Date Filing Date Title
US202063022392P 2020-05-08 2020-05-08
US63/022,392 2020-05-08
US202063024372P 2020-05-13 2020-05-13
US63/024,372 2020-05-13
US202063027814P 2020-05-20 2020-05-20
US63/027,814 2020-05-20
US202063029338P 2020-05-22 2020-05-22
US63/029,338 2020-05-22
US202063031286P 2020-05-28 2020-05-28
US63/031,286 2020-05-28
US202063033045P 2020-06-01 2020-06-01
US63/033,045 2020-06-01
US202063036683P 2020-06-09 2020-06-09
US63/036,683 2020-06-09
US202063039939P 2020-06-16 2020-06-16
US63/039,939 2020-06-16
US202063046465P 2020-06-30 2020-06-30
US63/046,465 2020-06-30
US202063057767P 2020-07-28 2020-07-28
US63/057,767 2020-07-28
US202063090667P 2020-10-12 2020-10-12
US63/090,667 2020-10-12
US202063113450P 2020-11-13 2020-11-13
US63/113,450 2020-11-13
US202163153784P 2021-02-25 2021-02-25
US63/153,784 2021-02-25
US202163170368P 2021-04-02 2021-04-02
US63/170,368 2021-04-02
PCT/US2021/031442 WO2021226560A1 (fr) 2020-05-08 2021-05-07 Anticorps contre sars-cov-2

Publications (1)

Publication Number Publication Date
CA3177169A1 true CA3177169A1 (fr) 2021-11-11

Family

ID=76250434

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3177169A Pending CA3177169A1 (fr) 2020-05-08 2021-05-07 Anticorps contre sars-cov-2

Country Status (11)

Country Link
EP (1) EP4146690A1 (fr)
JP (1) JP2023525039A (fr)
KR (1) KR20230010676A (fr)
AU (1) AU2021268361A1 (fr)
BR (1) BR112022022523A2 (fr)
CA (1) CA3177169A1 (fr)
CL (1) CL2022003085A1 (fr)
CO (1) CO2022017670A2 (fr)
IL (1) IL297988A (fr)
MX (1) MX2022013886A (fr)
WO (1) WO2021226560A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231031T1 (hr) * 2020-02-26 2023-12-22 Vir Biotechnology, Inc. Protutijela protiv sars-cov-2
JP7116256B1 (ja) 2020-04-02 2022-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片
CR20220660A (es) 2020-06-03 2023-02-17 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
CA3183367A1 (fr) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Molecules de liaison a l'antigene ciblant le sars-cov-2
IL300720A (en) 2020-08-26 2023-04-01 Flagship Pioneering Innovations Vi Llc Antigen binding molecules targeting Sars-cov-2
WO2022263638A1 (fr) * 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anticorps anti-sars-cov-2 et leur utilisation dans le traitement d'une infection par le sars-cov-2
CA3225575A1 (fr) * 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anticorps anti-glycoproteine de spicule du sars-cov-2 et fragments de liaison a l'antigene
WO2023201256A1 (fr) * 2022-04-12 2023-10-19 Vir Biotechnology, Inc. Thérapies par anticorps à haute dose contre une infection par le sars-cov-2
US11993644B2 (en) 2022-05-06 2024-05-28 Generate Biomedicines, Inc. Antigen binding molecules targeting SARS-CoV-2
US20230365658A1 (en) * 2022-05-16 2023-11-16 Lawrence Livermore National Security, Llc REPAIRED THERAPEUTIC AND PROPHYLACTIC ANTIBODIES AGAINST SARS-CoV-2 VARIANTS
WO2023235827A2 (fr) * 2022-06-03 2023-12-07 The Rockefeller University Anticorps inhibant les coronavirus
WO2024006472A1 (fr) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Anticorps qui se lient à de multiples sarbecovirus
WO2024081269A1 (fr) * 2022-10-10 2024-04-18 Dixit Rohan Combinaisons thérapeutiques et méthodes de traitement de covid longue
WO2024102674A1 (fr) 2022-11-13 2024-05-16 Generate Biomedicines, Inc. Molécules de liaison à l'antigène ciblant sars-cov-2
CN117362421A (zh) * 2022-12-02 2024-01-09 中国科学院微生物研究所 一种针对新冠病毒rbd的广谱单克隆抗体、其制备方法及应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0861893A3 (fr) 1991-09-19 1999-11-10 Genentech, Inc. Expression de haut niveau d'immunoglobulines
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
US7498415B2 (en) 2003-09-24 2009-03-03 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody against human insulin-like growth factor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
ES2923641T3 (es) 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
WO2016181357A1 (fr) 2015-05-13 2016-11-17 Zumutor Biologics, Inc. Protéine afucosylée, cellule exprimant ladite protéine et procédés associés
WO2019024979A1 (fr) 2017-07-31 2019-02-07 Institute For Research In Biomedicine Anticorps à domaines fonctionnels dans la région de coude
JP7387611B2 (ja) 2017-09-22 2023-11-28 ウーシー バイオロジクス アイルランド リミテッド 新規二重特異性ポリペプチド複合体

Also Published As

Publication number Publication date
KR20230010676A (ko) 2023-01-19
EP4146690A1 (fr) 2023-03-15
JP2023525039A (ja) 2023-06-14
WO2021226560A1 (fr) 2021-11-11
BR112022022523A2 (pt) 2023-01-10
CO2022017670A2 (es) 2023-03-07
MX2022013886A (es) 2022-11-30
AU2021268361A1 (en) 2022-12-08
IL297988A (en) 2023-01-01
CL2022003085A1 (es) 2023-09-01

Similar Documents

Publication Publication Date Title
US11168128B2 (en) Antibodies against SARS-CoV-2 and methods of using the same
CA3177169A1 (fr) Anticorps contre sars-cov-2
US20240059757A1 (en) Antibodies against sars-cov-2 and methods of using the same
CA3166627A1 (fr) Anticorps diriges contre le sras-cov-2 et leurs procedes d'utilisation
WO2021203053A1 (fr) Immunothérapie ciblant une région conservée dans des coronavirus sras
WO2022204202A1 (fr) Anticorps qui se lient à de multiples sarbecovirus
CA3180477A1 (fr) Therapies a base d'anticorps contre une infection a sars-cov-2
CA3194162A1 (fr) Anticorps contre le sars-cov-2
WO2022115486A1 (fr) Anticorps se liant à plusieurs bétacoronavirus
CA3197537A1 (fr) Anticorps contre les virus de la grippe a
TW202204395A (zh) 抗sars-cov-2之抗體及使用其之方法
TW202210505A (zh) 抗sars-cov-2之抗體
WO2024006472A1 (fr) Anticorps qui se lient à de multiples sarbecovirus
WO2024118998A2 (fr) Anticorps anti-sars-cov-2 modifiés et leurs méthodes d'utilisation
WO2023230445A2 (fr) Anticorps largement neutralisants dirigés contre la neuraminidase de la grippe
TW202417477A (zh) 與多種嚴重急性呼吸道症候群β型冠狀病毒結合之抗體
WO2023245078A1 (fr) Anticorps anti-parvovirus et leurs utilisations
WO2024112818A1 (fr) Anticorps anti-sars-cov-2 modifiés et leurs utilisations
CN116745314A (zh) 针对sars-cov-2的抗体